Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Resilia tissue developed by Edwards Lifesciences linked to long-term benefits
Researchers tracked nearly 1,000 SAVR patients, presenting eight-year data at the Heart Valve Society’s annual meeting in Cairo, Egypt.
FDA warns that certain coronary imaging catheters are being removed from market over safety concerns
A catheter sheath detached during use and was left in the patient’s body. It was successfully removed, but the FDA said it is now evaluating the potential risk to others going forward. There is no official recall at this time.
Cardiologist-founded startup announces FDA clearance, first uses of new TAVR pacing system
“The device takes variability out of the procedure by giving the operator full control while automating ramp-up and back-up algorithms," according to a clinician who used the new technology. "The TAVR procedure is simplified, reducing physician and staff workload."
Death after 1 year more common for real-world low-risk TAVR patients than those treated in clinical trials
Real-world patients were still associated with "excellent" outcomes, but it is important for cardiologists and patients alike to know as much as possible about the odds of survival following treatment.
FDA clears catheter-based 4D visualization platform for complex heart procedures
The new technology from LUMA Vision allows operators to deliver 2D and 4D ultrasound images in real time. The advanced catheter was built with maneuverability and increased visibility in mind.

doctor examines patient data on their tablet

TAVR or SAVR? ChatGPT could help cardiologists decide

Researchers asked ChatGPT to make treatment decisions for patients with severe aortic stenosis, comparing its answers to the recommendations of a full heart team.

TAVR JenaValve Trilogy Heart Valve System pure AR

Cardiologists make history, perform first-ever transcaval TAVR for pure aortic regurgitation

The 65-year-old male patient presented with a long medical history and many comorbidities, making surgery too risky.

Q&A: Interventional cardiologist details key breakthroughs in tricuspid valve replacement and repair

How have recent FDA approvals for Edwards Lifesciences and Abbott changed patient care? Andrew Rassi, MD, answered that question—and many more—in a new interview.

Boston Scientific recalls premixed embolic agent after two deaths

There have been a total of 11 incidents so far, including seven injuries and two deaths. Boston Scientific said the agent can still be used if operators follow specific instructions during lower GI bleed embolization procedures.

New cardiac imaging strategy could reduce ICA, PCI rates

Radiologists with Massachusetts General Hospital found that the selective use of cardiac CT and AI-based CAD evaluations could make a significant impact on patient care.

Video of Gregg Stone, MD, explaining the late-breaking RELIEVE-HF trial he presented at ACC.24 this week. #ACC24 #ACC2024

Inter-atrial shunt in RELIEVE-HF improves symptoms in HFrEF, but not HFpEF

Gregg Stone, MD, explains the details of the late-breaking RELIEVE-HF trial at ACC.24, where an inter-atrial shunt improved symptoms in HFrEF, but not in HFpEF patients.

FDA grants new imaging tool for CTO interventions its breakthrough device designation

The new device delivers real-time OCT visualization during revascularization procedures.

TAVR, SAVR both linked to low reintervention rates after five years

While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team's full analysis is available in JACC: Cardiovascular Interventions.

Interventional Cardiology

Resilia tissue developed by Edwards Lifesciences linked to long-term benefits

FDA warns that certain coronary imaging catheters are being removed from market over safety concerns

Cardiologist-founded startup announces FDA clearance, first uses of new TAVR pacing system

Death after 1 year more common for real-world low-risk TAVR patients than those treated in clinical trials

FDA clears catheter-based 4D visualization platform for complex heart procedures